Home Newsfeeds B of A Securities Downgrades Denbury to Underperform, Announces $71 Price Target

B of A Securities Downgrades Denbury to Underperform, Announces $71 Price Target

B of A Securities analyst Doug Leggate downgrades Denbury (NYSE:DEN) from Neutral to Underperform and announces $71 price target.

byBenzinga Newsdesk

July 19, 2022

1 minute read

B of A Securities analyst Doug Leggate downgrades Denbury (NYSE:DEN) from Neutral to Underperform and announces $71 price target.

Loop Capital Initiates Coverage On Procore Technologies with Buy Rating, Announces Price Target of $70

By Benzinga Newsdesk

December 22, 6:50 AM

Loop Capital analyst Mark Schappel initiates coverage on Procore Technologies (NYSE:PCOR) with a Buy rating and announces Price Target of $70.

PCOR

Analyst Ratings

JP Morgan Downgrades Enfusion: Here’s What You Need To Know

By Benzinga Insights

January 30, 1:00 PM

JP Morgan downgraded its rating of Enfusion (NYSE:ENFN) to Underweight with a price target of $9.00, changing its…

ENFN

Global
News

“Tesla ‘Giga India’ Potential Reignited With Reports Of Planned Visit” – Teslarati

By Happy Mohamed

May 16, 2:49 PM

https://www.teslarati.com/tesla-elon-musk-visit-india/ Tesla CEO Elon Musk and other top Tesla executives are expected to visit India later this week to discuss numerous supply-related issues and opportunities. Being

TSLA

CTI BioPharma Q4 EPS $(0.14) Vs $(0.38) Last Year, Sales $21.10M Miss $23.67M Estimate

By Benzinga Newsdesk

March 6, 7:28 AM

CTI BioPharma (NASDAQ:CTIC) reported quarterly losses of $(0.14). This is a 63.16 percent increase over losses of $(0.38) per share from the same period last year. The company reported quarterly sales of $21.10 million

CTIC

B of A Securities Downgrades Denbury to Underperform, Announces $71 Price Target

Related Posts

Loop Capital Initiates Coverage On Procore Technologies with Buy Rating, Announces Price Target of $70

JP Morgan Downgrades Enfusion: Here’s What You Need To Know

“Tesla ‘Giga India’ Potential Reignited With Reports Of Planned Visit” – Teslarati

CTI BioPharma Q4 EPS $(0.14) Vs $(0.38) Last Year, Sales $21.10M Miss $23.67M Estimate